Sarah L. Blair
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sarah L. Blair has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
Andrew C. Kummel
Department of Chemistry and Biochemistry, University of California, San Diego, CA
6 shared publications- William C. Trogler
Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA 92093, USA
6 shared publications James Wang
Department of Nanoengineering, University of California, San Diego, CA
5 shared publicationsAnna Weiss
Department of Breast Surgery, MD Anderson, Houston, TX, 77930, USA
4 shared publicationsErin P. Ward
University of California San Diego
4 shared publicationsJessica Wang-Rodriguez
Department of Pathology, University of California, San Diego, CA, USA
4 shared publications
Latest Publications
- Open Access
A Local and Abscopal Effect Observed with Liposomal Encapsulation of Intratumorally Injected Oncolytic Adenoviral Therapy
This study evaluated the in vivo therapeutic efficacy of oncolytic serotype 5 adenovirus TAV255 in CAR-deficient tumors. In vitro experiments were performed with cell lines that expressed different levels of CAR (HEK293, A549, CT26, 4T1, and MCF-7). Low CAR cells, such as CT26, were poorly transduced by Ad in vitro unless the adenovirus was encapsulated in liposomes. However, the CT26 tumor in an immune-competent mouse model responded to the unencapsulated TAV255; 33% of the tumors were induced into complete remission, and mice with complete remission rejected the rechallenge with cancer cell injection. Encapsulation of TAV255 improves its therapeutic efficacy by transducing more CT26 cells, as expected from in vitro results. In a bilateral tumor model, nonencapsulated TAV255 reduced the growth rate of the locally treated tumors but had no effect on the growth rate of the distant tumor site. Conversely, encapsulated TAV255-infected CT26 induced a delayed growth rate of both the primary injected tumor and the distant tumor, consistent with a robust immune response. In vivo, intratumorally injected unencapsulated adenoviruses infect CAR-negative cells with only limited efficiency. However, unencapsulated adenoviruses robustly inhibit the growth of CAR-deficient tumors, an effect that constitutes an ‘in situ vaccination’ by stimulating cytotoxic T cells.
Open AccessA Local and Abscopal Effect Observed with Liposomal Encapsulation of Intratumorally Injected Oncolytic Adenoviral Therapy
This study evaluated the in vivo therapeutic efficacy of oncolytic serotype 5 adenovirus TAV255 in CAR-deficient tumors. In vitro experiments were performed with cell lines that expressed different levels of CAR (HEK293, A549, CT26, 4T1, and MCF-7). Low CAR cells, such as CT26, were poorly transduced by Ad in vitro unless the adenovirus was encapsulated in liposomes. However, the CT26 tumor in an immune-competent mouse model responded to the unencapsulated TAV255; 33% of the tumors were induced into complete remission, and mice with complete remission rejected the rechallenge with cancer cell injection. Encapsulation of TAV255 improves its therapeutic efficacy by transducing more CT26 cells, as expected from in vitro results. In a bilateral tumor model, nonencapsulated TAV255 reduced the growth rate of the locally treated tumors but had no effect on the growth rate of the distant tumor site. Conversely, encapsulated TAV255-infected CT26 induced a delayed growth rate of both the primary injected tumor and the distant tumor, consistent with a robust immune response. In vivo, intratumorally injected unencapsulated adenoviruses infect CAR-negative cells with only limited efficiency. However, unencapsulated adenoviruses robustly inhibit the growth of CAR-deficient tumors, an effect that constitutes an ‘in situ vaccination’ by stimulating cytotoxic T cells.
- 11 November 2019
- Published by Elsevier in The American Journal of Surgery
- Vol. 220 (1) , 153-160
Treatment for occult breast cancer: A propensity score analysis of the National Cancer Database
- 11 November 2019
- Published by Elsevier in The American Journal of Surgery
- Vol. 220 (1) , 153-160
Treatment for occult breast cancer: A propensity score analysis of the National Cancer Database
- 6 June 2019
- Published by Wiley in Journal of Surgical Oncology
- Vol. 120 (2) , 148-159
Adherence to surgical and oncologic standards improves survival in breast cancer patients
Background: Adherence to evidence‐based standards can lead to improved outcomes for patients with breast cancer. However, adherence rates to standards and their effects on patient outcomes are unknown.Objectives: To examine adherence rates to standards compiled by the American College of Surgeons Clinical Research Program and its effects on patient outcomes.Methods: Using the National Cancer Database (2004‐2015), we identified cohorts of breast cancer patients: clinical T1N0M0 under age of 70 (cT1), clinical T2N0M0 or T3N0M0 (cT2/3), and clinical M0 and pathologic N2 or N3 (pN2/3). Standards included negative margins, any adjuvant therapy, and two or more lymph nodes (LNs) examined (for cT1 or cT2/3 patients) or more than 10 LNs examined (for pN2/3 patients). We performed Kaplan‐Meier and Cox proportional hazards analysis.Results: We identified 318 853 (65.0%) cT1, 164 593 (67.3%) cT2/3, and 77 626 (67.7%) pN2/3 patients who met the standards. More than 90% of patients had negative margins and adjuvant therapy, but less than 80% met LN standards. The median overall survival (OS) was significantly longer for patients who met the standards. Individual components of the standards were predictors of improved OS.Conclusions: One‐third of patients did not meet the evidence‐based standards in their treatment for breast cancer. Efforts to improve the knowledge of and adherence to these standards should be emphasized.
- 6 June 2019
- Published by Wiley in Journal of Surgical Oncology
- Vol. 120 (2) , 148-159
Adherence to surgical and oncologic standards improves survival in breast cancer patients
Background: Adherence to evidence‐based standards can lead to improved outcomes for patients with breast cancer. However, adherence rates to standards and their effects on patient outcomes are unknown.Objectives: To examine adherence rates to standards compiled by the American College of Surgeons Clinical Research Program and its effects on patient outcomes.Methods: Using the National Cancer Database (2004‐2015), we identified cohorts of breast cancer patients: clinical T1N0M0 under age of 70 (cT1), clinical T2N0M0 or T3N0M0 (cT2/3), and clinical M0 and pathologic N2 or N3 (pN2/3). Standards included negative margins, any adjuvant therapy, and two or more lymph nodes (LNs) examined (for cT1 or cT2/3 patients) or more than 10 LNs examined (for pN2/3 patients). We performed Kaplan‐Meier and Cox proportional hazards analysis.Results: We identified 318 853 (65.0%) cT1, 164 593 (67.3%) cT2/3, and 77 626 (67.7%) pN2/3 patients who met the standards. More than 90% of patients had negative margins and adjuvant therapy, but less than 80% met LN standards. The median overall survival (OS) was significantly longer for patients who met the standards. Individual components of the standards were predictors of improved OS.Conclusions: One‐third of patients did not meet the evidence‐based standards in their treatment for breast cancer. Efforts to improve the knowledge of and adherence to these standards should be emphasized.
- 3 September 2018
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 25 (12) , 3740-3746
Doppler Ultrasound-Visible SignalMark Microspheres are Better Identified than HydroMARK® Clips in a Simulated Intraoperative Setting in Breast and Lung Tissue
Background Preoperative breast and lung markers have significant drawbacks, including migration, patient discomfort, and scheduling difficulties. SignalMark is a novel localizer device with a unique...
- 3 September 2018
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 25 (12) , 3740-3746
Doppler Ultrasound-Visible SignalMark Microspheres are Better Identified than HydroMARK® Clips in a Simulated Intraoperative Setting in Breast and Lung Tissue
Background Preoperative breast and lung markers have significant drawbacks, including migration, patient discomfort, and scheduling difficulties. SignalMark is a novel localizer device with a unique...
- 9 July 2018
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 25 (10) , 2813-2817
ASBRS Great Debate: Sentinel Node Biopsy in Patients Over 70 Years of Age
Introduction Controversy over the need for sentinel node biopsy (SNB) continues to exist for the optimal treatment of breast cancer in patients ≥ 70 years of age, especially in those with lower-risk...
- 9 July 2018
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 25 (10) , 2813-2817
ASBRS Great Debate: Sentinel Node Biopsy in Patients Over 70 Years of Age
Introduction Controversy over the need for sentinel node biopsy (SNB) continues to exist for the optimal treatment of breast cancer in patients ≥ 70 years of age, especially in those with lower-risk...
- 17 August 2017
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Medical Imaging
- Vol. 37 (1) , 222-229
Extended Lifetime In Vivo Pulse Stimulated Ultrasound Imaging
An on-demand long-lived ultrasound contrast agent that can be activated with single pulse stimulated imaging (SPSI) has been developed using hard shell liquid perfluoropentane filled silica 500-nm nanoparticles for tumor ultrasound imaging. SPSI was tested on LnCAP prostate tumor models in mice; tumor localization was observed after intravenous (IV) injection of the contrast agent. Consistent with enhanced permeability and retention, the silica nanoparticles displayed an extended imaging lifetime of 3.3±1 days (mean±standard deviation). With added tumor specific folate functionalization, the useful lifetime was extended to 12 ± 2 days; in contrast to ligand-based tumor targeting, the effect of the ligands in this application is enhanced nanoparticle retention by the tumor. This paper demonstrates for the first time that IV injected functionalized silica contrast agents can be imaged with an in vivo lifetime ~500 times longer than current microbubble-based contrast agents. Such functionalized long-lived contrast agents may lead to new applications in tumor monitoring and therapy.
- 17 August 2017
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Medical Imaging
- Vol. 37 (1) , 222-229
Extended Lifetime In Vivo Pulse Stimulated Ultrasound Imaging
An on-demand long-lived ultrasound contrast agent that can be activated with single pulse stimulated imaging (SPSI) has been developed using hard shell liquid perfluoropentane filled silica 500-nm nanoparticles for tumor ultrasound imaging. SPSI was tested on LnCAP prostate tumor models in mice; tumor localization was observed after intravenous (IV) injection of the contrast agent. Consistent with enhanced permeability and retention, the silica nanoparticles displayed an extended imaging lifetime of 3.3±1 days (mean±standard deviation). With added tumor specific folate functionalization, the useful lifetime was extended to 12 ± 2 days; in contrast to ligand-based tumor targeting, the effect of the ligands in this application is enhanced nanoparticle retention by the tumor. This paper demonstrates for the first time that IV injected functionalized silica contrast agents can be imaged with an in vivo lifetime ~500 times longer than current microbubble-based contrast agents. Such functionalized long-lived contrast agents may lead to new applications in tumor monitoring and therapy.
- 1 August 2017
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 24 (10) , 3038-3047
Influence of Distance to Hospital and Insurance Status on the Rates of Contralateral Prophylactic Mastectomy, a National Cancer Data Base study
We evaluated the impact of travel distance and insurance status on contralateral prophylactic mastectomy (CPM) rates in breast cancer.
- 1 August 2017
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 24 (10) , 3038-3047
Influence of Distance to Hospital and Insurance Status on the Rates of Contralateral Prophylactic Mastectomy, a National Cancer Data Base study
We evaluated the impact of travel distance and insurance status on contralateral prophylactic mastectomy (CPM) rates in breast cancer.
- 12 June 2017
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 165 (2) , 403-409
Incidence and treatments of DCIS in octogenarians: grade matters
The purpose of this study is to better characterize the current incidence and treatment patterns of DCIS in women greater than 80 years of age (>80) and to evaluate the effect of grade on treatment efficacy.
- 12 June 2017
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 165 (2) , 403-409
Incidence and treatments of DCIS in octogenarians: grade matters
The purpose of this study is to better characterize the current incidence and treatment patterns of DCIS in women greater than 80 years of age (>80) and to evaluate the effect of grade on treatment efficacy.
- 5 January 2017
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 9 (2) , 1719-1727
Ultrasound Responsive Macrophase-Segregated Microcomposite Films for in Vivo Biosensing
Ultrasound imaging is a safe, low-cost, and in situ method for detecting in vivo medical devices. A poly(methyl-2-cyanoacrylate) film containing 2 μm boron-doped, calcined, porous silica microshells was developed as an ultrasound imaging marker for multiple medical devices. A macrophase separation drove the gas-filled porous silica microshells to the top surface of the polymer film by controlled curing of the cyanoacrylate glue and the amount of microshell loading. A thin film of polymer blocked the wall pores of the microshells to seal air in their hollow core, which served as an ultrasound contrast agent. The ultrasound activity disappeared when curing conditions were modified to prevent the macrophase segregation. Phase segregated films were attached to multiple surgical tools and needles and gave strong color Doppler signals in vitro and in vivo with the use of a clinical ultrasound imaging instrument. Postprocessing of the simultaneous color Doppler and B-mode images can be used for autonomous identification of implanted surgical items by correlating the two images. The thin films were also hydrophobic, thereby extending the lifetime of ultrasound signals to hours of imaging in tissues by preventing liquid penetration. This technology can be used as a coating to guide the placement of implantable medical devices or used to image and help remove retained surgical items.
- 5 January 2017
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 9 (2) , 1719-1727
Ultrasound Responsive Macrophase-Segregated Microcomposite Films for in Vivo Biosensing
Ultrasound imaging is a safe, low-cost, and in situ method for detecting in vivo medical devices. A poly(methyl-2-cyanoacrylate) film containing 2 μm boron-doped, calcined, porous silica microshells was developed as an ultrasound imaging marker for multiple medical devices. A macrophase separation drove the gas-filled porous silica microshells to the top surface of the polymer film by controlled curing of the cyanoacrylate glue and the amount of microshell loading. A thin film of polymer blocked the wall pores of the microshells to seal air in their hollow core, which served as an ultrasound contrast agent. The ultrasound activity disappeared when curing conditions were modified to prevent the macrophase segregation. Phase segregated films were attached to multiple surgical tools and needles and gave strong color Doppler signals in vitro and in vivo with the use of a clinical ultrasound imaging instrument. Postprocessing of the simultaneous color Doppler and B-mode images can be used for autonomous identification of implanted surgical items by correlating the two images. The thin films were also hydrophobic, thereby extending the lifetime of ultrasound signals to hours of imaging in tissues by preventing liquid penetration. This technology can be used as a coating to guide the placement of implantable medical devices or used to image and help remove retained surgical items.